Free Trial
NASDAQ:CERT

Certara (CERT) Stock Price, News & Analysis

Certara logo
$9.48 -0.76 (-7.38%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Certara Stock (NASDAQ:CERT)

Key Stats

Today's Range
$9.44
$10.03
50-Day Range
$9.78
$14.25
52-Week Range
$9.26
$19.18
Volume
3.40 million shs
Average Volume
1.05 million shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.83
Consensus Rating
Moderate Buy

Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Remove Ads

Certara Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

CERT MarketRank™: 

Certara scored higher than 86% of companies evaluated by MarketBeat, and ranked 123rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Certara has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Certara has only been the subject of 4 research reports in the past 90 days.

  • Read more about Certara's stock forecast and price target.
  • Earnings Growth

    Earnings for Certara are expected to grow by 28.57% in the coming year, from $0.28 to $0.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Certara is -48.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Certara is -48.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Certara has a PEG Ratio of 9.29. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Certara has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Certara's valuation and earnings.
  • Percentage of Shares Shorted

    4.88% of the float of Certara has been sold short.
  • Short Interest Ratio / Days to Cover

    Certara has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Certara has recently increased by 10.06%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Certara does not currently pay a dividend.

  • Dividend Growth

    Certara does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.88% of the float of Certara has been sold short.
  • Short Interest Ratio / Days to Cover

    Certara has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Certara has recently increased by 10.06%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Certara has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Certara this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for CERT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Certara to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Certara insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.39% of the stock of Certara is held by insiders.

  • Percentage Held by Institutions

    73.96% of the stock of Certara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Certara's insider trading history.
Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

CERT Stock News Headlines

Certara unveils advanced drug development simulator
Checking Back In On Certara: Unattractive Valuation
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

CERT Stock Analysis - Frequently Asked Questions

Certara's stock was trading at $10.65 on January 1st, 2025. Since then, CERT stock has decreased by 8.2% and is now trading at $9.78.
View the best growth stocks for 2025 here
.

Certara, Inc. (NASDAQ:CERT) announced its earnings results on Wednesday, November, 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The company's revenue was up 10.7% on a year-over-year basis.

Certara (CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

Top institutional shareholders of Certara include Kera Capital Partners Inc. (0.01%) and Versant Capital Management Inc. Insiders that own company stock include Mason P Slaine, Michael Andrew Schemick, Richard M Traynor, Matthew M Walsh, Leif E Pedersen, Patrick F Smith, Stephen M Mclean, Eran Broshy and Avatar Parent LP Eqt.
View institutional ownership trends
.

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Certara investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/06/2024
Today
4/03/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Prepackaged software
Sub-Industry
Computer Software
Current Symbol
NASDAQ:CERT
Fax
N/A
Employees
350
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.83
High Stock Price Target
$20.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+61.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
34.93
P/E Growth
9.29
Net Income
$-55,360,000.00
Pretax Margin
-8.52%

Debt

Sales & Book Value

Annual Sales
$385.15 million
Cash Flow
$0.68 per share
Price / Cash Flow
14.32
Book Value
$6.55 per share
Price / Book
1.49

Miscellaneous

Free Float
157,140,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
1.60
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CERT) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners